Table 4. Independent prognostic determinants of composite MACCE by univariate and multivariate analysis.
| Parameters | MACCE (+) (n = 84) | MACCE (-) (n= 183) | Univariate | Multivariate |
| p value | p value | |||
| Tele-ECG group | 24 (27.3) | 78 (42.4%) | 0.016 | 0.003 |
| Age (years) | 64.5 ± 14 | 61.4 ± 13 | 0.081 | |
| Male | 68 (77%) | 155 (84%) | 0.179 | |
| Diabetes | 31 (35%) | 59 (32%) | 0.68 | |
| Hypertension | 48 (54.5%) | 91 (49.5%) | 0.44 | |
| Smoking | 19 (21.6%) | 27 (14.7%) | 0.169 | |
| Hyperlipidemia | 28 (31.8%) | 78 (42.4%) | 0.111 | |
| Prior myocardial infarction | 14 (15.9%) | 20 (10.9%) | 0.245 | |
| Prior stroke | 1 (1.1%) | 7 (3.8%) | 0.444 | |
| Prior CABG | 3 (3.4%) | 6 (3.3%) | 1 | |
| Prior PCI | 5 (5.7%) | 11 (6.0%) | 1 | |
| Prior valvular heart disease | 1 (1.1%) | 5 (2.7%) | 0.667 | |
| Number of diseased vessels | 0.023 | 0.128 | ||
| 1 | 32 (31%) | 27 (16%) | ||
| 2 | 40 (39%) | 71 (42%) | ||
| 3 | 30 (29%) | 71 (42%) | ||
| Location of lesion | 0.43 | |||
| LAD | 45 (47%) | 77 (48%) | ||
| LCX | 11 (12%) | 25 (16%) | ||
| RCA | 39 (41%) | 59 (37%) | ||
| LAD involved | 45 (51.1%) | 79 (42.9%) | 0.242 | |
| Use of drug eluting stent | 25 (28%) | 69 (38%) | 0.11 | |
| Prehospital on-scene time, hours (IQR) | 3.8 (1.63-7.51) | 3.2 (1.88-9.6) | 0.329 | |
| D2BT_min, median (IQR) | 117 (87-182) | 91 (75-135) | 0.022 | |
| D2BT ≤ 90 minutes goal | 29 (35%) | 85 (43%) | 0.06 | |
| Parameters at presentation | ||||
| SBP (mmHg) | 130 ± 28 | 136 ± 31 | 0.09 | |
| DBP (mmHg) | 79 ± 18 | 84 ± 21 | 0.058 | |
| Heart rate (per minute) | 79 ± 21 | 75 ± 20 | 0.102 | |
| WBC (/μl) | 11,253 ± 3,642 | 10,496 ± 3,252 | 0.085 | |
| NLR, median (IQR) | 3.9 (2.2-7.45) | 2.9 (1.68-5.2) | 0.003 | 0.372 |
| GRACE score | 141 ± 32 | 132 ± 34 | 0.047 | |
| GRACE score ≥ 144 | 41 (48.8) | 67 (36.6%) | 0.062 | |
| Initial troponin I | 13.8 ± 25.4 | 7.9 ± 20.9 | 0.06 | |
| Cholesterol (mg/dl) | 174 ± 38 | 180 ± 46 | 0.299 | |
| Triglyceride (mg/dl) | 137 ± 86 | 141 ± 121 | 0.795 | |
| Creatine (mg/dl) | 1.2 ± 1 | 1.2 ± 1.1 | 0.823 | |
| Glucose (gm/dL) | 194 ± 105 | 171 ± 79 | 0.077 | |
| Peak CK (μ/ml) | 2,364 ± 2,201 | 2,645 ± 2,251 | 0.333 | |
| Peak CK-MB (μ/ml) | 115 ± 2,201 | 135 ± 2,251 | 0.234 | |
| Peak Troponin I (μ/ml) | 77.3 ± 101.7 | 86.4 ± 103.5 | 0.497 | |
| LV ejection fraction (%) | 43 ± 10 | 42 ± 11 | 0.639 | |
| Moderate to severe MR (%) | 19 (23%) | 21 (74%) | 0.027 | 0.029 |
CABG, coronary artery bypass grafting; CAD, coronary artery disease; CK, creatinine kinase; CK-MB, creatinine kinase MB isoenzyme; DBP, diastolic blood pressure; D2BT, door to balloon time; ECG, electrocardiography; GRACE, Global Registry of Acute Coronary Events; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; LV, left ventricle; MACCE, major cardiac and cerebral adverse events; MR, mitral regurgitation; NLR, neutrophil-lymphocyte ratio; PCI, percutaneous coronary intervention; RCA, right coronary artery; SBP, systolic blood pressure; WBC, white blood cell.